<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24193" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Physiology, Leptin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dornbush</surname>
            <given-names>Sean</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Aeddula</surname>
            <given-names>Narothama R.</given-names>
          </name>
          <aff>Deaconess HS, IN University School Med</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sean Dornbush declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Narothama Aeddula declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24193.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Leptin is a peptide hormone released from adipose tissue and encoded by the obese (<italic toggle="yes">ob</italic>) gene. While leptin's role is&#x000a0;classically&#x000a0;described in the regulation of appetite, neuroendocrine function, and energy homeostasis, it seems to influence several&#x000a0;other physiological processes. These include metabolism, endocrine regulation, and immune function, with possible other functions still awaiting characterization. Leptin abnormalities have associations with a variety of metabolic syndromes, particularly obesity. The study of leptin physiology has contributed to our understanding of energy homeostasis, and it seems likely that it will play a pivotal role in developing an effective treatment and a solution to the growing obesity epidemic. The total body fat mass index (BMI), metabolic hormones, and gender are the factors that have the greatest effect on circulating plasma leptin concentrations. Women have higher levels of circulating leptin compared to men.<xref ref-type="bibr" rid="article-24193.r1">[1]</xref></p>
      </sec>
      <sec id="article-24193.s2" sec-type="Cellular Level&#x0000d;&#x0000a;">
        <title>Cellular Level
</title>
        <p>
<bold>Biology</bold>
</p>
        <p>Leptin is a peptide hormone synthesized by white adipose tissue. The leptin gene (<italic toggle="yes">LEP or </italic>ob) is on chromosome 7q31.3.<xref ref-type="bibr" rid="article-24193.r2">[2]</xref>&#x000a0; The mature protein is comprised of 146 amino acids and produced through mRNA-directed protein synthesis.<xref ref-type="bibr" rid="article-24193.r3">[3]</xref> Its structure is like the proinflammatory cytokines found throughout the body, such as interleukin 6 and granulocyte colony-stimulating factor.<xref ref-type="bibr" rid="article-24193.r4">[4]</xref> The amount of leptin in the blood is directly proportional to the amount of adipose tissue. Leptin exerts its actions by binding to leptin receptors (LR) on the surface of cells. Leptin receptors are present on neuronal, hepatic, pancreatic, cardiac, and intestinal tissue.</p>
        <p>
<bold>Mechanism</bold>
</p>
        <p>The LR belongs to the glycoprotein 130 family of cytokine receptors and comprises 6-isoform. Of these isoforms, isoform-b is the most characterized. Its long-form is the receptor subtype that principally mediates the activation of critical second messenger pathways and normal leptin action.<xref ref-type="bibr" rid="article-24193.r5">[5]</xref> The main signaling pathway for the LR is the JAK-STAT pathway. As leptin binds it to dimerize the LR. This dimerization leads to JAK2 tyrosine kinase phosphorylating three tyrosine residues that serve as docking sites for the proteins SHP2, STAT5, and STAT3. The function of SHP is to participate in ERK signaling, and the function of STAT 5 is as yet undetermined. STAT 3 acts as a transcription factor responsible for mediating leptin&#x02019;s primary actions.&#x000a0;</p>
      </sec>
      <sec id="article-24193.s3" sec-type="Function">
        <title>Function</title>
        <p>Leptin's principal site of action is the brain, specifically in the brainstem and hypothalamus. The major sites of action in the brainstem are the solitary tract and the ventral tegmental area. Leptin acts here to modulate satiety and the control of reward and aversion. In the hypothalamus, the lateral hypothalamic area and the ventromedial, dorsomedial, ventral pre mammillary, and arcuate (ARC) nuclei are leptin&#x02019;s major sites of action. The activation of these areas leads to various changes, including in the thyroid, gonadal, adrenocorticotropic hormone-cortisol growth hormone axes, and changes in whole-brain cognition, emotions, memory, and structure. Many of these relationships are still being worked out.<xref ref-type="bibr" rid="article-24193.r6">[6]</xref><xref ref-type="bibr" rid="article-24193.r7">[7]</xref> The most well-known of them is leptin&#x02019;s actions on the ARC nucleus. The ARC nucleus is a major player in regulating appetite and energy homeostasis. It contains orexigenic agouti-related protein/neuropeptide Y-containing (AgRP/NPY) neurons and anorexigenic proopiomelanocortin-containing (POMC) neurons. Leptin acts on the ARC nucleus by stimulating POMC-containing neurons and inhibiting AgRP/NPY containing neurons- having the total effect of decreased appetite.</p>
        <p>Taken as a whole, leptin&#x02019;s function in the body pertains to regulating the balance between food intake and energy expenditure. The classic primary physiologic role of leptin is to serve as a marker of long-term energy stores for the central nervous system (CNS).<xref ref-type="bibr" rid="article-24193.r8">[8]</xref> As the amount of adipose tissue decreases, the amount of leptin produced and crossing the blood-brain barrier decreases. The CNS interrupts the decline in leptin as a signal of energy deficit, which triggers a cascade of responses to help the body deal with the stress of starvation. To counteract the energy deficit, the CNS increases hunger while also promoting energy-sparing neuroendocrine and autonomic mechanisms, including decreased sympathetic nervous system tone, thyroid, and reproductive hormone levels, energy expenditure, and growth. As this signal, leptin is the catalyst for the body's transition into a starvation mode, a global adaption aimed towards increasing food intake and decreasing energy expenditure. A decrease in serum leptin then is the starvation signal for the CNS. As food intake increases and the level of adipose tissue becomes excessive, there is a concurrent rise in the production and secretion of leptin into the bloodstream. With increased leptin comes an inhibition of the body&#x02019;s starvation mode, thereby&#x000a0;promoting reduced food intake and increased energy expenditure to counteract the current energy surplus.</p>
      </sec>
      <sec id="article-24193.s4" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Leptin deficiency or&#x000a0;resistance&#x000a0;is associated with dysregulation of cytokine production, increased susceptibility to infections, autoimmune disorders, malnutrition, and inflammatory responses.</p>
        <p>
<bold>Pathophysiology and Clinical Relevance </bold>
</p>
        <p>Hypoleptinemia</p>
        <p>Complete leptin deficiency results in the clinical phenotypes of severe obesity, impaired satiety, intensive hyperphagia, constant food-seeking behavior, recurrent bacterial infections, hyperinsulinemia, liver steatosis, dyslipidemia, and hypogonadotropic hypogonadism.<xref ref-type="bibr" rid="article-24193.r9">[9]</xref><xref ref-type="bibr" rid="article-24193.r10">[10]</xref> These phenotypes highlight the variety of roles leptin has in the body, many not well understood and still actively under investigation. Congenital forms of hypoleptinemia result from mutations in<italic toggle="yes"> LEP</italic> or the LR gene and are known as congenital leptin deficiencies (CLD). Acquired hypoleptinemias share some of these same phenotypes and are usually due to conditions that cause a low body weight. Examples of acquired conditions are lipodystrophy syndromes and hypothalamic amenorrhea.</p>
        <p>Hyperleptinemia</p>
        <p>Hyperleptinemia is associated with leptin resistance&#x000a0;-&#x000a0;specifically resistance to the anorectic and body weight-reducing effects of leptin. Hyperleptinemia and leptin resistance are components of common obesity. Evidence for this association is a direct correlation between serum leptin concentrations and body fat percentage where obese individuals had higher leptin serum levels and adipocyte <italic toggle="yes">LEP</italic> mRNA content compared with normal-weight individuals. Also, leptin serum levels and adipocyte <italic toggle="yes">LEP</italic> mRNA content fall with weight reduction. The mechanism of resistance appears related to defects in leptin transport across the blood-brain barrier or intracellular signaling mechanisms downstream of the LR. Other diseases associated with hyperleptinemia include nonalcoholic fatty liver disease, Rabson&#x02013;Mendenhall syndrome, neurodegenerative disorders, depression, and food addiction.<xref ref-type="bibr" rid="article-24193.r11">[11]</xref></p>
        <p>Therapeutics</p>
        <p>Recombinant forms of leptin are under investigation in the treatment of both hypoleptinemia and hyperleptinemia-related syndrome.&#x000a0;Initially studied to reverse obesity, leptin replacement has only reversed obesity in leptin-deficient conditions, with replacement in typically obese individuals with elevated leptin levels showing limited efficacy. It has FDA approval for the treatment of congenital or acquired generalized lipodystrophy (non-HIV-related). Particular studies show leptin replacement has efficacy&#x000a0;in reversing&#x000a0;some&#x000a0;abnormalities present in the above-mentioned syndromes, but these conditions are not yet a recognized indication for the&#x000a0;use&#x000a0;of recombinant leptin as&#x000a0;a treatment.<xref ref-type="bibr" rid="article-24193.r12">[12]</xref></p>
      </sec>
      <sec id="article-24193.s5">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24193&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24193">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24193/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24193">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24193.s6">
        <title>References</title>
        <ref id="article-24193.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grinspoon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gulick</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Askari</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Landt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Vignati</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bowsher</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Herzog</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Klibanski</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Serum leptin levels in women with anorexia nervosa.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>1996</year>
            <month>Nov</month>
            <volume>81</volume>
            <issue>11</issue>
            <fpage>3861</fpage>
            <page-range>3861-3</page-range>
            <pub-id pub-id-type="pmid">8923829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24193.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gong</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Bi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pratley</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Weintraub</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Genomic structure and promoter analysis of the human obese gene.</article-title>
            <source>J Biol Chem</source>
            <year>1996</year>
            <month>Feb</month>
            <day>23</day>
            <volume>271</volume>
            <issue>8</issue>
            <fpage>3971</fpage>
            <page-range>3971-4</page-range>
            <pub-id pub-id-type="pmid">8626726</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24193.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wasim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Awan</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Najam</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>HN</given-names>
              </name>
            </person-group>
            <article-title>Role of Leptin Deficiency, Inefficiency, and Leptin Receptors in Obesity.</article-title>
            <source>Biochem Genet</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>54</volume>
            <issue>5</issue>
            <fpage>565</fpage>
            <page-range>565-72</page-range>
            <pub-id pub-id-type="pmid">27313173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24193.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peelman</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zabeau</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moharana</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Savvides</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Tavernier</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>20 years of leptin: insights into signaling assemblies of the leptin receptor.</article-title>
            <source>J Endocrinol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>223</volume>
            <issue>1</issue>
            <fpage>T9</fpage>
            <page-range>T9-23</page-range>
            <pub-id pub-id-type="pmid">25063754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24193.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allison</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>20 years of leptin: connecting leptin signaling to biological function.</article-title>
            <source>J Endocrinol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>223</volume>
            <issue>1</issue>
            <fpage>T25</fpage>
            <page-range>T25-35</page-range>
            <pub-id pub-id-type="pmid">25232147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24193.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amjad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baig</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zahid</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tariq</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rehman</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Association between leptin, obesity, hormonal interplay and male infertility.</article-title>
            <source>Andrologia</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>51</volume>
            <issue>1</issue>
            <fpage>e13147</fpage>
            <pub-id pub-id-type="pmid">30255520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24193.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farr</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Gavrieli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mantzoros</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Leptin applications in 2015: what have we learned about leptin and obesity?</article-title>
            <source>Curr Opin Endocrinol Diabetes Obes</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>353</fpage>
            <page-range>353-9</page-range>
            <pub-id pub-id-type="pmid">26313897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24193.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flier</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Maratos-Flier</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Leptin's Physiologic Role: Does the Emperor of Energy Balance Have No Clothes?</article-title>
            <source>Cell Metab</source>
            <year>2017</year>
            <month>Jul</month>
            <day>05</day>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-26</page-range>
            <pub-id pub-id-type="pmid">28648981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24193.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Funcke</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>von Schnurbein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lennerz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lahr</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Debatin</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Fischer-Posovszky</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wabitsch</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Monogenic forms of childhood obesity due to mutations in the leptin gene.</article-title>
            <source>Mol Cell Pediatr</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <pub-id pub-id-type="pmid">26567097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24193.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farooqi</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>O'Rahilly</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>20 years of leptin: human disorders of leptin action.</article-title>
            <source>J Endocrinol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>223</volume>
            <issue>1</issue>
            <fpage>T63</fpage>
            <page-range>T63-70</page-range>
            <pub-id pub-id-type="pmid">25232148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24193.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peters</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Antel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>F&#x000f6;cker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hinney</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sch&#x000e9;le</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Albayrak</surname>
                <given-names>&#x000d6;</given-names>
              </name>
              <name>
                <surname>Hebebrand</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The association of serum leptin levels with food addiction is moderated by weight status in adolescent psychiatric inpatients.</article-title>
            <source>Eur Eat Disord Rev</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>618</fpage>
            <page-range>618-628</page-range>
            <pub-id pub-id-type="pmid">30252189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24193.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paz-Filho</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mastronardi</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Licinio</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Leptin treatment: facts and expectations.</article-title>
            <source>Metabolism</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>146</fpage>
            <page-range>146-56</page-range>
            <pub-id pub-id-type="pmid">25156686</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
